A bibliometric analysis of the current state and future directions of osteoporosis pharmacological treatment

对骨质疏松症药物治疗现状及未来方向的文献计量分析

阅读:1

Abstract

INTRODUCTION: Osteoporosis is a major health threat, particularly with the aging population in China. Medication remains a cornerstone of management, and bibliometric analysis can provide insights into current research status and future directions. METHODS: Relevant literature from the Science Citation Index Core Collection (2015-2024) was analyzed using bibliometric methods. Visual maps were generated with Citespace 6.3R3 and VOSviewer 1.6.19 to assess research trends and hotspots. RESULTS: A total of 2,738 publications were included, showing a steady growth in research since 2015. The United States led in output, with the University of Toronto as the most productive institution. Brandi, Maria Luisa, and Kanis JA were the most influential authors, while Osteoporosis International and The Journal of Bone and Mineral Research were the most cited journals. Key themes included extracellular vesicles, romosozumab, bisphosphonates, and breast cancer, with recent attention on targeted drug delivery, treatment efficacy, and medication management. Emerging keywords from 2022 to 2023, such as exosomes, inflammation, and osteogenic differentiation, reflected advances in therapeutic mechanisms and clinical applications. CONCLUSION: Future research will likely emphasize targeted drug delivery, clinical efficacy and safety, and molecular targeted therapies, with the development of new anti-osteoporosis drugs remaining a key focus.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。